Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia

Next Previous
Search
Trial Profile

A Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabedersen (Primary) ; Dexamethasone
  • Indications COVID 2019 infections; Pneumonia; Respiratory insufficiency
  • Focus Therapeutic Use
  • Sponsors Oncotelic Therapeutics

Most Recent Events

  • 13 Mar 2023 Status changed to completed, according to an Oncotelic Therapeutics media release.
  • 13 Mar 2023 According to an Oncotelic Therapeutics media release, this trial was completed in South America.
  • 12 Oct 2022 According to a Oncotelic Therapeutics media release, Oncotelic awarded BARDA funding for development of OT-101 for long COVID

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top